Discover HEMANGEOLTM
The First and Only
FDA-Approved Treatment for Proliferating Infantile Hemangioma Requiring Systemic Therapy
Proven Efficacy
  • 60% of patients reached complete or nearly complete resolution of infantile hemangioma by 6 months versus 4% of patients on placebo
  • 88% of patients on HEMANGEOLTM showed improvement after 5 weeks of treatment1

Learn More

Safety Profile
  • The following adverse events were observed with incidence of less than 1%
    • Cardiac disorders
    • Decreased blood glucose
    • Decreased heart beat
    • Alopecia
    • Urticaria
  • Fewer than 2% of patients discontinued treatment due to adverse reactions
  • The most common adverse reactions to HEMANGEOLTM (occurring ≤10% of patients) were
    • Sleep disorders
    • Aggravated respiratory tract infections
    • Diarrhea
    • Vomiting

Learn More

BID Dosing
  • 3.4 mg/kg in 2 divided doses daily for 6 months chosen as the optimal treatment regimen in double-blind clinical trial
  • Dosing Calculator for determining the appropriate dose for your patients
  • Unique graduated syringe with bottle adapter for convenient and safe dosing by parents and caregivers

Learn More

Reference: 1. Data on file. Pierre Fabre Pharmaceuticals, Inc., 2014.

Dosing Calculator*

Use the Dosing Calculator to determine the recommended dosing volume of HEMANGEOLTM according to your patient's weight.

Choose your patient's weight

Next
*The dosing calculator is for healthcare professional use only. Parents and caregivers must consult with their physician about proper dosing of HEMANGEOLTM for their infant.


INDICATION
HEMANGEOLTM oral solution contains the beta-adrenergic blocker propranolol hydrochloride and is indicated for the treatment of proliferating infantile hemangioma requiring systemic therapy.

IMPORTANT SAFETY INFORMATION
HEMANGEOLTM is contraindicated in the following conditions:
  • Premature infants with corrected age <5 weeks
  • Infants weighing less than 2 kg
  • Known hypersensitivity to propranolol or any of the excipients
  • Asthma or history of bronchospasm
  • Heart rate <80 beats per minute, greater than first degree heart block, or decompensated heart failure
  • Blood pressure < 50/30 mmHg
  • Pheochromocytoma
HEMANGEOLTM prevents the response of endogenous catecholamines to correct hypoglycemia and masks the adrenergic warning signs of hypoglycemia, particularly tachycardia, palpitations and sweating.

HEMANGEOLTM can cause hypoglycemia in children, especially when they are not feeding regularly or are vomiting; withhold the dose under these conditions. Hypoglycemia may present in the form of seizures, lethargy, or coma. If a child has clinical signs of hypoglycemia, parents should discontinue HEMANGEOLTM and call their health care provider immediately or take the child to the emergency room.

Concomitant treatment with corticosteroids may increase the risks of hypoglycemia.

HEMANGEOLTM may cause or worsen bradycardia or hypotension. Monitor heart rate and blood pressure after treatment initiation or increase in dose. Discontinue treatment if severe (<80 beats per minute) or symptomatic bradycardia or hypotension (systolic blood pressure <50 mmHg) occurs.

HEMANGEOLTM can cause bronchospasm; do not use in patients with asthma or a history of bronchospasm. Interrupt treatment in the event of a lower respiratory tract infection associated with dyspnea and wheezing.

HEMANGEOLTM may worsen circulatory function in patients with congestive heart failure or increase the risk of stroke in PHACE syndrome patients with severe cerebrovascular anomalies. Investigate infants with large facial infantile hemangioma for potential arteriopathy associated with PHACE syndrome prior to HEMANGEOLTM therapy.

HEMANGEOLTM will interfere with epinephrine used to treat serious anaphylaxis.

The most frequently reported adverse reactions to HEMANGEOLTM (occurring ≥10% of patients) were sleep disorders, aggravated respiratory tract infections, diarrhea, and vomiting. Adverse reactions led to treatment discontinuation in fewer than 2% of treated patients.

The most common ( >3% more often on HEMANGEOLTM than on placebo) adverse reactions reported in the a total of 424 patients treated with HEMANGEOLTM 1.2 mg/kg/day or 3.4 mg/kg/day were sleep disorder (17.5%; 16.1%), bronchitis (8%; 13.4%), peripheral coldness (8%; 6.7%), agitation (8.5%; 4.5%), diarrhea (4.5%; 6.3%), somnolence (5%; 0.9%), nightmare (2%; 6.3%), irritability (5.5%; 1.3%), decreased appetite (2.5%; 3.6%), and abdominal pain (3.5%; 0.4%), respectively.

Adverse events such as cardiac disorders, urticaria, alopecia, hypogylcemia, and bradycardia occurred in less than 1%.

Safety and effectiveness for infantile hemangioma have not been established in pediatric patients greater than 1 year of age.

Please see Full Prescribing Information and Medication Guide .

Important Safety Information
Overlay